InDex Pharmaceuticals: Q4 – Approaching the next step
Research Note
2021-02-25
10:44
Redeye reiterates its Base case of SEK 4,5 following the release of today's year-end report. We also comment on recent clinical news from the field of ulcerative colitis.
FE
Filip Einarsson
Disclosures and disclaimers